PFIZER Pharmaceuticals has announced its new meningococcal Group B vaccine, Trumenba, is now available via private prescription through healthcare providers and pharmacies.
Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B, providing another option for immunisation against the rare but devastating disease, Pfizer said.
It should be noted that the vaccine is not listed on the National Immunisation Program (NIP) or the Pharmaceutical Benefits Scheme.
It was first listed in the Australian Register of Therapeutic Goods 14 Sep last year.
Visit pfizer.com.au for the PI or call Pfizer Medical Information on 1800 675 229.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Apr 18
